339 related articles for article (PubMed ID: 29275313)
1. Tumor-infiltrating Lymphocytes Predict the Chemotherapeutic Outcomes in Patients with Stage IV Colorectal Cancer.
Shibutani M; Maeda K; Nagahara H; Fukuoka T; Iseki Y; Matsutani S; Kashiwagi S; Tanaka H; Hirakawa K; Ohira M
In Vivo; 2018; 32(1):151-158. PubMed ID: 29275313
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study.
Shibutani M; Maeda K; Nagahara H; Fukuoka T; Matsutani S; Kashiwagi S; Tanaka H; Hirakawa K; Ohira M
BMC Cancer; 2018 Apr; 18(1):371. PubMed ID: 29614981
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Significance of the Tumor-infiltrating Programmed Cell Death-1
Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Matsutani S; Hirakawa K; Ohira M
Anticancer Res; 2017 Aug; 37(8):4165-4172. PubMed ID: 28739701
[TBL] [Abstract][Full Text] [Related]
4. A new method for evaluating tumor-infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (H-E)-stained tumor sections.
Iseki Y; Shibutani M; Maeda K; Nagahara H; Fukuoka T; Matsutani S; Kashiwagi S; Tanaka H; Hirakawa K; Ohira M
PLoS One; 2018; 13(4):e0192744. PubMed ID: 29698402
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer.
Schweiger T; Berghoff AS; Glogner C; Glueck O; Rajky O; Traxler D; Birner P; Preusser M; Klepetko W; Hoetzenecker K
Clin Exp Metastasis; 2016 Oct; 33(7):727-39. PubMed ID: 27449756
[TBL] [Abstract][Full Text] [Related]
6. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M
Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186
[TBL] [Abstract][Full Text] [Related]
7. Increased number of forkhead box P3+ tumor-infiltrating lymphocytes correlates with high preoperative albumin level and better survival in patients with stage II or III colorectal cancer.
Wang DL; Liu YY; Gu YL; Qin Y; Ji HF; Wu LH; Qi N; Su D; Huang SH; Zhang YQ
Tumour Biol; 2015 Jul; 36(7):5407-14. PubMed ID: 25697896
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A
Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403
[TBL] [Abstract][Full Text] [Related]
9. Budding and tumor-infiltrating lymphocytes - combination of both parameters predicts survival in colorectal cancer and leads to new prognostic subgroups.
Lang-Schwarz C; Melcher B; Haumaier F; Lang-Schwarz K; Rupprecht T; Vieth M; Sterlacci W
Hum Pathol; 2018 Sep; 79():160-167. PubMed ID: 29787819
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features.
Nazemalhosseini-Mojarad E; Mohammadpour S; Torshizi Esafahani A; Gharib E; Larki P; Moradi A; Amin Porhoseingholi M; Asadzade Aghdaei H; Kuppen PJK; Zali MR
J Cell Physiol; 2019 Apr; 234(4):4768-4777. PubMed ID: 30370522
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Pruneri G; Gray KP; Vingiani A; Viale G; Curigliano G; Criscitiello C; Láng I; Ruhstaller T; Gianni L; Goldhirsch A; Kammler R; Price KN; Cancello G; Munzone E; Gelber RD; Regan MM; Colleoni M
Breast Cancer Res Treat; 2016 Jul; 158(2):323-31. PubMed ID: 27372069
[TBL] [Abstract][Full Text] [Related]
12. CD8⁺ tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma.
Fujii H; Arakawa A; Utsumi D; Sumiyoshi S; Yamamoto Y; Kitoh A; Ono M; Matsumura Y; Kato M; Konishi K; Shiga T; Sano S; Sakaguchi S; Miyagawa-Hayashino A; Takahashi K; Uezato H; Miyachi Y; Tanioka M
Int J Cancer; 2014 May; 134(10):2393-402. PubMed ID: 24243586
[TBL] [Abstract][Full Text] [Related]
13. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
[TBL] [Abstract][Full Text] [Related]
14. The value of tumor-infiltrating lymphocytes and CD8 expression as a predictor of response to anthracycline-based neoadjuvant chemotherapy in invasive breast carcinoma of no special type.
Miskad UA; Rifai RA; Masadah R; Nelwan B; Ahmad D; Cangara H; Prihantono P; Zainuddin AA; Rahawarin H
Breast Dis; 2021; 40(S1):S9-S14. PubMed ID: 34092582
[TBL] [Abstract][Full Text] [Related]
15. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating Immune Cells in H&E-stained Sections of Colorectal Cancer Tissue as a Reasonable Immunological Biomarker.
Matsutani S; Shibutani M; Maeda K; Nagahara H; Fukuoka T; Iseki Y; Kashiwagi S; Tanaka H; Hirakawa K; Ohira M
Anticancer Res; 2018 Dec; 38(12):6721-6727. PubMed ID: 30504382
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy.
Cha YJ; Park EJ; Baik SH; Lee KY; Kang J
Sci Rep; 2019 Aug; 9(1):11617. PubMed ID: 31406179
[TBL] [Abstract][Full Text] [Related]
18. Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer.
Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2017 Oct; 37(10):5623-5630. PubMed ID: 28982879
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of tumor-infiltrating FoxP3+ regulatory T cells and CD8+ cytotoxic T cells in microsatellite-unstable gastric cancers.
Kim KJ; Lee KS; Cho HJ; Kim YH; Yang HK; Kim WH; Kang GH
Hum Pathol; 2014 Feb; 45(2):285-93. PubMed ID: 24331841
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
